Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. (September 2015)

• Record Type: Journal Article
• Authors: Chen, Yan; Qian, Tian; Zhang, Dongmei; Yan, Heng; Hao, Fei
• Is Part Of: Immunotherapy. Volume 7:Number 9(2015:Sep.)
• Page Start: 1023
• Page End: 1037
• Publication Date: 2015-09
• Subjects: anti-IL-17 agents -- brodalumab -- efficacy -- ixekizumab -- meta-analysis -- psoriasis -- safety -- secukinumab; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt.15.50
• Languages: English
• ISSNs: 1750-743X

Abstract

To evaluate the therapeutic efficacy and safety of anti-IL-17 agents in the treatment of psoriasis, we performed a systemic review and meta-analysis of the relevant published clinical trials, collectively referred to as secukinumab, ixekizumab and brodalumab. 2668 patients in eight eligible trials with psoriasis were selected for the present meta-analysis. The estimated pooled PASI75, PSAI90, physician's global assessment (PGA; clear) showed significant improvements for psoriasis patients who received biotherapy compared with placebo. The results of headache, upper respiratory tract infection and infections demonstrated that there was no significant difference between the biotherapy and placebo groups. But the results of nasopharyngitis demonstrated that there was a significant difference for biotherapy group. The results showed that anti-IL-17 agents were effective and safe for psoriasis patients.